title: Induction of protective anti-CTL epitope responses against HER-2-positive breast cancer based on multivalent T7 phage nanoparticles.
abstract: We report here the development of multivalent T7 bacteriophage nanoparticles displaying an immunodominant H-2k(d)-restricted CTL epitope derived from the rat HER2/neu oncoprotein. The immunotherapeutic potential of the chimeric T7 nanoparticles as anti-cancer vaccine was investigated in BALB/c mice in an implantable breast tumor model. The results showed that T7 phage nanoparticles confer a high immunogenicity to the HER-2-derived minimal CTL epitope, as shown by inducing robust CTL responses. Furthermore, the chimeric nanoparticles protected mice against HER-2-positive tumor challenge in both prophylactic and therapeutic setting. In conclusion, these results suggest that CTL epitope-carrying T7 phage nanoparticles might be a promising approach for development of T cell epitope-based cancer vaccines.
authors.affiliation: Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
authors.forename: Somayeh
authors.initials: S
authors.lastname: Pouyanfard
authors.forename: Taravat
authors.initials: T
authors.lastname: Bamdad
authors.forename: Hamidreza
authors.initials: H
authors.lastname: Hashemi
authors.forename: Mojgan
authors.initials: M
authors.lastname: Bandehpour
authors.forename: Bahram
authors.initials: B
authors.lastname: Kazemi
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D017123:Bacteriophage T7 / Q000737:chemistry / Q000276:immunology*; D001943:Breast Neoplasms / Q000235:genetics / Q000276:immunology*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology; D036022:Capsid Proteins / Q000276:immunology; D002460:Cell Line; D061505:Cell Surface Display Techniques; D003602:Cytotoxicity, Immunologic; D018984:Epitopes, T-Lymphocyte / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007371:Interferon-gamma / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000235:genetics / Q000276:immunology; D051379:Mice; D008969:Molecular Sequence Data; D053758:Nanoparticles / Q000737:chemistry; D010455:Peptides / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D011485:Protein Binding / Q000276:immunology; D051381:Rats; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D036022:Capsid Proteins; D018984:Epitopes, T-Lymphocyte; D007074:Immunoglobulin G; D007371:Interferon-gamma; D015847:Interleukin-4; D008070:Lipopolysaccharides; D010455:Peptides; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins